Immune checkpoint inhibitors, a class of oncological treatments that enhance antitumour
immunity, can trigger neurological adverse events closely resembling paraneoplastic …

Immune checkpoint inhibitors lead to effective antitumour responses but also to immune-
related adverse events (irAEs), which affect the nervous system in 1–5% of patients …

Autoimmune diseases arise when the immune system mistakenly attacks the body's own
tissues, leading to chronic inflammation and organ damage. These disorders are complex …

Background Immune checkpoint inhibitor-related encephalitis (ICI-encephalitis) is not well
characterised and diagnostic and prognostic biomarkers are lacking. We aimed to …

Background and Objectives The clinical course and the risk of chronicity of neurologic
immune-related adverse events (n-irAEs) associated with immune checkpoint inhibitors …

Background Immune checkpoint inhibitors (ICIs) work by activating the immune system, a
mechanism that may also cause immune-related adverse events (irAEs). This study seeks to …

The clinical and outcomes diversity of CNS-irAEs suggests different pathogenic
mechanisms, which need to be understood to establish more effective and specific treatment …

The concept that many neurologic and psychiatric disorders of unknown cause are immune-
mediated has evolved fast during the past 20 years. The main contribution to the expansion …

Despite the growing evidence supporting the existence of CNS involvement in acute and
chronic graft-versus-host disease (CNS-GvHD), the characteristics and course of the …

Intravesical instillation‐based immunotherapy for bladder‐preservation of bladder cancer
(BCa) treatment has not been explored. In the current study, two irrigated nano‐formulations …